Next Article in Journal
First Isolation of a Giant Virus from Wild Hirudo medicinalis Leech: Mimiviridae isolation in Hirudo medicinalis
Next Article in Special Issue
Genetic Modification of Hematopoietic Stem Cells as a Therapy for HIV/AIDS
Previous Article in Journal
Human Respiratory Syncytial Virus Memphis 37 Grown in HEp-2 Cells Causes more Severe Disease in Lambs than Virus Grown in Vero Cells
Previous Article in Special Issue
Newer Gene Editing Technologies toward HIV Gene Therapy
 
 
Article

Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice

1
Department of Virology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
2
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
3
Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA
*
Author to whom correspondence should be addressed.
Viruses 2013, 5(11), 2898-2919; https://doi.org/10.3390/v5112898
Received: 18 October 2013 / Revised: 15 November 2013 / Accepted: 18 November 2013 / Published: 22 November 2013
(This article belongs to the Special Issue Gene Therapy for Retroviral Infections)
Over the past 15 years we have been investigating an alternative approach to treating HIV-1/AIDS, based on the creation of a disease-resistant immune system through transplantation of autologous, gene-modified (HIV-1-resistant) hematopoietic stem and progenitor cells (GM-HSPC). We propose that the expression of selected RNA-based HIV-1 inhibitors in the CD4+ cells derived from GM-HSPC will protect them from HIV-1 infection and results in a sufficient immune repertoire to control HIV-1 viremia resulting in a functional cure for HIV-1/AIDS. Additionally, it is possible that the subset of protected T cells will also be able to facilitate the immune-based elimination of latently infected cells if they can be activated to express viral antigens. Thus, a single dose of disease resistant GM-HSPC could provide an effective treatment for HIV-1+ patients who require (or desire) an alternative to lifelong antiretroviral chemotherapy. We describe herein the results from several pilot clinical studies in HIV-1 patients and our strategies to develop second generation vectors and clinical strategies for HIV-1+ patients with malignancy who require ablative chemotherapy as part of treatment and others without malignancy. The important issues related to stem cell source, patient selection, conditioning regimen and post-infusion correlative studies become increasingly complex and are discussed herein. View Full-Text
Keywords: HIV-1; stem cells; gene therapy; non-ablative conditioning; transplantation HIV-1; stem cells; gene therapy; non-ablative conditioning; transplantation
Show Figures

Figure 1

MDPI and ACS Style

DiGiusto, D.L.; Stan, R.; Krishnan, A.; Li, H.; Rossi, J.J.; Zaia, J.A. Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice. Viruses 2013, 5, 2898-2919. https://doi.org/10.3390/v5112898

AMA Style

DiGiusto DL, Stan R, Krishnan A, Li H, Rossi JJ, Zaia JA. Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice. Viruses. 2013; 5(11):2898-2919. https://doi.org/10.3390/v5112898

Chicago/Turabian Style

DiGiusto, David L., Rodica Stan, Amrita Krishnan, Haitang Li, John J. Rossi, and John A. Zaia. 2013. "Development of Hematopoietic Stem Cell Based Gene Therapy for HIV-1 Infection: Considerations for Proof of Concept Studies and Translation to Standard Medical Practice" Viruses 5, no. 11: 2898-2919. https://doi.org/10.3390/v5112898

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop